Schering Sees No Impact From Rx Imports; Portfolio Not Attractive To "Parallel Traders"
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering still believes importation is the wrong approach to lowering U.S. drug costs. "Parallel importers" have little incentive to pass on savings to patients, and FDA cannot adequately regulate the supply chain, CEO Fred Hassan says.